PROVIREX Genome Editing Therapies
Biotechnology Research • 
Hamburg, Hamburg, Germany • 11-20 Employees
Company overview
| Headquarters | Luruper Hauptstraße 1, Start-up Labs Bahrenfeld, Hamburg, 22547, DE |
| Websites | |
| Keywords | Stem Cells, GMP, HIV, Clinical Trials, Nanoparticles, AAV, Clean Rooms, Atmp, Gene Therapy, Genome Editing, Retrovirus, Lentiviral Vectors, Nanobodies, T Cells, Recombinase, Htlv |
| Founded | 2019 |
| Employees | 11-20 |
Key Contact at PROVIREX Genome Editing Therapies
Jan-Uwe Claas
Chief Executive Officer
PROVIREX Genome Editing Therapies Email Formats
PROVIREX Genome Editing Therapies uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@provirex.de), used 55.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@provirex.de | 55.6% |
{first name}.{last name} | john.doe@provirex.de | 44.4% |
About PROVIREX Genome Editing Therapies
PROVIREX GmbH is a privately-held biotech company developing first-in-class advanced therapy medicinal products (ATMPs). PROVIREX is a spin-off of the Leibniz Institute for Virology (LIV) and is based in Hamburg, Germany. PROVIREX’s technology is based on error-free genome editing for eradication of life-threatening persistent virus infection. PROVIREX employs site-specific recombinase-based genome surgery technology to precisely excise chromosomally integrated viral genomes (proviruses). The major advantage of site-specific recombinases is that they function independently of host DNA repair. Therefore, in contrast to other gene editing technologies, they act with nucleotide precision producing completely error-free recombinants. The engineered recombinase Brec1 excises HIV-1 proviruses with high specificity from the genome of infected cells. PROVIREX’s proprietary Brec1 technology is currently entering clinical testing as first-in-human phase Ib/IIa clinical trials aiming to remove HIV-1 using gene editing of the peripheral blood (hematopoietic) stem cells of people living with HIV. PROVIREX has built GMP-compliant clean rooms at the tecHHub in Hamburg, which have also been approved by GenTSV as S3** laboratories and in which Brec1 technology will be administered as gene therapy in the future. In addition, PROVIREX will also offer CAR-T cancer therapy for people living with HIV, which is unique in Germany! PROVIREX is currently preparing its application for manufacturing authorization with the drug regulatory authority. PROVIREX is also researching ways to administer Brec1 technology more easily and directly, e.g. via LNPs. In another research project, PROVIREX is further developing another recombinase, this time to treat HTLV-1, a retrovirus closely related to HIV that causes an aggressive form of blood cancer and a progressive neurological disease.
PROVIREX Genome Editing Therapies revenue & valuation
| Annual revenue | $1,026,660 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,300,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
PROVIREX Genome Editing Therapies has 4 employees across 3 departments.
Departments
Number of employees
Funding Data
PROVIREX Genome Editing Therapies has never raised funding before.
PROVIREX Genome Editing Therapies Tech Stack
Discover the technologies and tools that power PROVIREX Genome Editing Therapies's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Video players
Video players
JavaScript libraries
Marketing automation
JavaScript libraries
UI frameworks
Page builders
JavaScript libraries
Web servers
JavaScript libraries
Italy
United Kingdom
United States
Bangladesh
Frequently asked questions
4.8
40,000 users
